“FMSRAI held demonstrations at the company’s offices across the country today and now we are planning a strike,” said a spokesperson at the Federation of Medical and Sales Representatives Association of India (FMSRAI). The spokesperson confirmed that 700 members of the sales force went on casual mass leave across the country on Monday.
The employees and the federation have to give 15 days’ notice before they go on a strike. The federation said it would inform the company soon about the strike. It said about 120 employees from the antibiotics department were also expected to be laid off soon.
The company did not confirm the mass leaves or share any information regarding the negotiations. “The information you have received is factually incorrect,” said a company spokesperson in an e-mail response. “AstraZeneca has kept its employees continuously informed and updated on its business strategy. Through the course of the restructuring, we have absorbed as many employees as possible, and those in roles that were impacted have been provided financial and transitional support, including compensation packages, counselling and job placement services.” The company claimed to have followed all applicable laws and regulation.
The development comes at a time when the employees of erstwhile Ranbaxy are fighting for better working conditions and agitating against Sun Pharmaceutical’s “arbitrary transfers” and non-payment of wages. Sun Pharmaceutical acquired Ranbaxy in 2014. On Thursday, the Bombay High Court ordered Sun Pharmaceutical to disburse salaries of 48 sales representatives who have not been paid since May.
Sunil Goel, managing director at HR consultancy firm GlobalHunt, said: “The pharma industry used to work on thick margins earlier but the margins have shrunk now. Now companies need to improve productivity by enforcing optimisation of resources like manpower.”
Rituparna Chakraborty, senior vice-president at TeamLease Services, said the pharmaceuticals industry was going through a bad patch. “There is no point carrying people with you if it is becoming unviable and unsustainable,” she added.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)